XNASILMN
Market cap21bUSD
Dec 27, Last price
135.27USD
1D
0.23%
1Q
3.96%
Jan 2017
5.65%
Name
Illumina Inc
Chart & Performance
P/E
—
P/S
4.76
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
1.18%
Rev. gr., 5y
6.21%
Revenues
4.50b
-1.75%
Net income
-1.16b
L-73.64%
CFO
478m
+21.94%
Earnings
Feb 06, 2025
Profile
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2023‑00 | 2022‑00 | 2021‑00 | 2019‑12 | 2018‑12 | 2017‑12 | 2017‑00 | 2016‑00 | |
| Income | |||||||||
Revenues | 4,504,000 -0.49% | 4,584,000 1.28% | 4,526,000 39.73% | ||||||
Cost of revenue | 3,114,000 | 2,933,000 | 2,557,000 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | 1,390,000 | 1,651,000 | 1,969,000 | ||||||
NOPBT Margin | 30.86% | 36.02% | 43.50% | ||||||
Operating Taxes | 44,000 | 68,000 | 122,000 | ||||||
Tax Rate | 3.17% | 4.12% | 6.20% | ||||||
NOPAT | 1,346,000 | 1,583,000 | 1,847,000 | ||||||
Net income | (1,161,000) -252.36% | (4,404,000) -677.95% | 762,000 16.16% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 67,000 | 9,000 | (451,000) | ||||||
BB yield | -0.30% | -0.03% | 0.79% | ||||||
| Debt | |||||||||
Debt current | 86,000 | 1,248,000 | 71,000 | ||||||
Long-term debt | 2,863,000 | 2,975,000 | 3,243,000 | ||||||
Deferred revenue | 63,000 | 63,000 | |||||||
Other long-term liabilities | 620,000 | 649,000 | 915,000 | ||||||
Net debt | 1,699,000 | 1,975,000 | 1,762,000 | ||||||
| Cash flow | |||||||||
Cash from operating activities | 478,000 | 392,000 | 545,000 | ||||||
CAPEX | (195,000) | (466,000) | (208,000) | ||||||
Cash from investing activities | (231,000) | (591,000) | (1,069,000) | ||||||
Cash from financing activities | (1,210,000) | 1,000,000 | (51,000) | ||||||
FCF | 1,693,000 | 1,887,000 | 1,531,000 | ||||||
| Balance | |||||||||
Cash | 1,054,000 | 2,037,000 | 1,339,000 | ||||||
Long term investments | 196,000 | 211,000 | 213,000 | ||||||
Excess cash | 1,024,800 | 2,018,800 | 1,325,700 | ||||||
Stockholders' equity | (18,000) | 1,147,000 | 5,504,000 | ||||||
Invested Capital | 8,645,000 | 9,546,000 | 12,834,300 | ||||||
ROIC | 12.53% | 14.15% | 23.18% | ||||||
ROCE | 16.11% | 15.53% | 13.97% | ||||||
| EV | |||||||||
Common stock shares outstanding | 158,000 | 157,000 | 151,000 | ||||||
Price | 139.24 -63.40% | 202.20 -46.85% | 380.44 2.82% | ||||||
Market cap | 21,999,920 -61.70% | 31,745,400 -44.74% | 57,446,440 4.91% | ||||||
EV | 23,698,920 | 33,720,400 | 59,208,440 | ||||||
EBITDA | 1,822,000 | 2,045,000 | 2,220,000 | ||||||
EV/EBITDA | 13.01 | 16.49 | 26.67 | ||||||
Interest | 77,000 | 26,000 | 61,000 | ||||||
Interest/NOPBT | 5.54% | 1.57% | 3.10% | ||||||